Recently, Goertek Optics and Nearview Technology officially inked a strategic cooperation agreement, heralding a profound partnership centered on optical technology innovation and large-scale product manufacturing within the realm of non-invasive detection.

This collaboration is grounded in the continuous growth of each entity's capabilities. Nearview Technology has a long-standing and deep-rooted presence in the medical-engineering integration sphere. Its non-invasive blood glucose detection solution, which leverages multi-micro-spatial offset Raman scattering (mμSORS) spectroscopy technology, published its clinical research results in the esteemed journal Nature Metabolism in 2025. Concurrently, it is making strides in establishing a mass production base in Xiaogan, boasting a planned annual capacity of millions of units and currently at a pivotal juncture transitioning from technical validation to full-scale manufacturing.

On the other hand, Goertek Optics is unwavering in its commitment to bolstering its prowess in precision optics and micro-nano manufacturing. In June 2026, its 12-inch AR micro-nano optical wafer base commenced operations in Lingang. That same October, China's inaugural 12-inch DUV lithography and etching mass production line was officially launched, elevating wafer-level optical manufacturing capabilities to semiconductor-grade precision and large-scale mass production standards.

Per the agreement, both parties will harness Nearview Technology's accumulated expertise in optical technology within the life and health sector, coupled with Goertek Optics' storied legacy in precision optics R&D, large-scale mass production, and smart manufacturing. Together, they will collaborate across three key dimensions: R&D synergy, product supply, and technical support.